Ozone Preconditioning: Waking up the dragon

Background

Since the 1970s, doctors have reported an odd pattern: small doses of ozone gas, delivered by routes that bypass the lungs and go straight into the blood, seemed to produce clinical benefits rather than the toxic effects normally associated with an oxidising gas. Through the 1980s, physicians treating HIV patients described improvements after ozone administration, and later work suggested the gas could enhance immune function. Over time, an increasingly long list of conditions was reported to respond favourably to ozone, including autoimmune disorders, peripheral vascular disease, fibromyalgia, neurodegenerative diseases, kidney and gastrointestinal disorders, wound healing, and - in more recent reports - COVID-19 pneumonitis. What was missing was a coherent explanation for how a molecule capable of causing oxidative damage could also drive protective, healing responses.

Study design

This is a narrative review and hypothesis article rather than a new clinical trial or laboratory experiment. The authors, a radiologist and a maternal-fetal medicine specialist, drew together existing clinical reports, case observations and mechanistic literature on ozone's biological effects and organised them around a single explanatory framework. Their approach was to reinterpret previously published findings on ozone through the lens of oxidative preconditioning - the idea that a brief, controlled, sub-toxic exposure to an oxidising stress can trigger the body's own protective machinery - rather than to collect new primary data.

Findings

The authors describe ozone administered in small, controlled doses as producing what they term a mild, transient oxidative stress. Rather than causing lasting harm, this brief exposure appears to switch on adaptive defences: antioxidant systems are upregulated, immune signalling is modulated, and cellular repair processes are activated. Drawing on the wider literature, they report that this pattern has been associated with improvements across a broad range of conditions - from autoimmune disease and peripheral vascular disease to fibromyalgia, neurodegenerative disease, renal and gastrointestinal disorders, chronic wounds, and, in some reports, reduced viral load and improved clinical symptoms in intensive-care patients with COVID-19 pneumonitis. The authors frame ozone's safety profile, when used at these controlled doses, as broadly comparable to that of common over-the-counter medicines.

What the authors concluded

The authors argue that ozone's clinical effects are best understood not through a simple molecular or single-target model, but through the concept of hormesis - a controlled, low-dose stressor triggering a disproportionately protective, adaptive response. They describe this as part of a broader shift in thinking, away from disease models based purely on individual molecules and cells and towards models that account for the body's overall energy and stress-response dynamics. On this basis, they propose that oxidative preconditioning with ozone has therapeutic potential across a wide range of acute and chronic conditions, and they call for this mechanism to be investigated further.

Limitations of this study

As a narrative review and hypothesis paper, this work does not present new controlled experiments or original patient data; it draws its conclusions from previously published clinical reports and mechanistic studies conducted by others, many of which vary in design and quality. The selection and interpretation of this evidence reflects the authors' own theoretical framework, which carries a risk of selection bias, and the proposed hormetic mechanism is not directly tested within the paper itself. Readers should treat the central hypothesis as a plausible explanatory model rather than an established, experimentally confirmed mechanism, pending confirmation through dedicated controlled trials.